Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (AZN)
NASDAQ:AZN
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.1Last Year’s EPS
0.99Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -0.34%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong start to 2025 with significant revenue and EPS growth, driven by pipeline advancements and strategic global manufacturing. However, challenges such as Medicare Part D redesign and headwinds in China and Soliris revenue present areas of concern.Company Guidance
During AstraZeneca's Q1 2025 earnings call, the company provided several key metrics and guidance updates. Total revenue saw a growth of 10%, driven by a strong demand for innovative medicines across all major regions. The core operating profit increased by 12%, while the core earnings per share (EPS) rose by 21%, benefitting from a lower tax rate due to settlements. AstraZeneca secured 13 approvals in key regions, highlighting the value of its medicines. The company's emerging markets, excluding China, saw a revenue increase of 17%, while China itself experienced a 5% growth, or 9% when adjusting for Pulmicort sales decline. AstraZeneca aims to deliver at least 20 new medicines by 2030, with nine already approved. The company is reiterating its full-year 2025 guidance, anticipating high single-digit percentage growth in total revenue and low double-digit percentage growth in core EPS at constant exchange rates.Strong Revenue Growth
Total revenue grew by 10% in the first quarter, with product sales increasing by 9% and Alliance revenue growing by 42%.
Core EPS and Operating Profit Increase
Core EPS increased by 21% and core operating profit increased by 12%, reflecting strong operating leverage and a lower tax rate.
Significant Pipeline Advancements
Secured 13 approvals in key regions, announced five positive Phase III results, and made progress towards 20 new medicines by 2030.
Promising Oncology Developments
Enhertu total revenues grew 34%, and positive Phase III results for camizestrant and MATTERHORN offer promising growth opportunities.
Resilient Global Manufacturing Network
31 manufacturing sites globally with dual-source supply for the majority of medicines, providing resilience to regional disruptions.
---
AZN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AZN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $69.93 | $71.71 | +2.55% |
Feb 06, 2025 | $69.96 | $71.36 | +2.00% |
Nov 12, 2024 | $63.89 | $64.29 | +0.63% |
Jul 25, 2024 | $78.14 | $76.97 | -1.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Astrazeneca Plc (AZN) report earnings?
Astrazeneca Plc (AZN) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Astrazeneca Plc (AZN) earnings time?
Astrazeneca Plc (AZN) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AZN EPS forecast?
AZN EPS forecast for the fiscal quarter 2025 (Q2) is 1.1.
---
